Building Breakout Companies: Creandum X Jack&Jill + Scarlet
On Tuesday 3rd March, join Entrepreneurs First for an evening conversation with two of our standout portfolio companies, Jack & Jill and Scarlet.
Hosted by Creandum — one of Europe’s leading early-stage VCs and an investor in both companies — this panel will explore what the founder journey really looks like: from starting at zero, to raising seed capital, and building toward Series A.
Hear firsthand how these founders went from idea-stage to venture-backed companies. Together, we'll explore turning early conviction into investor belief, what early-stage VCs are actually looking for, the realities of building in today's market + lessons learned along the way.
Panellists:
- Nelson Casata, Vice President @ Creandum
- Matthew Wilson, Co-founder and CEO @ Jack & Jill
- James Dewar, Co-founder and CEO @ Scarlet
Agenda:
6pm: Arrival + networking
6.45pm: Panel
7.30pm: Q&A
8pm: Networking
9pm: End of Event
We care about curated rooms and attendance is not guaranteed. You'll find out whether you have been allocated a space within 3 working days of registering.
About Entrepreneurs First: EF turns exceptional individuals into funded founders. Some might have an early idea, others may need a cofounder. What matters is their potential. We back these founders first, then give them a bridge to Silicon Valley. To date, our companies are worth > $13B.
About Creandum: Creandum is a leading European early-stage venture capital firm backing Europe’s most ambitious founders, including Lovable, Klarna, Spotify, Trade Republic, Depop, Bolt, Pleo, Epidemic Sound and many more. Creandum has hubs in Stockholm, Berlin, London, and San Francisco.
About Jack&Jill: Established in 2025, Jack & Jill develops AI-powered recruitment agents. The firm has created two conversational AI systems: Jack, which interacts with job seekers to understand their skills, experience, and career objectives, and Jill, which engages with hiring teams to capture the requirements of open roles and identify suitable candidates. In October 2025 they announced $20 million in a seed funding round led by Creandum.
About Scarlet: Founded in 2021, Scarlet’s mission is to hasten the transition to universally accessible and affordable healthcare across the globe. They deliver on that mission by certifying software and AI medical devices in a way that is optimised to the realities of fast-paced development and cutting-edge innovation. In August 2022, Scarlet raised £6M in a Seed round led by Creandum, and in June 2024 raised a $17.5M Series A led by Atomico.